Rapid Therapeutic Science Laboratories, Inc. Quarterly Debt-to-equity in % from Q4 2016 to Q2 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Rapid Therapeutic Science Laboratories, Inc. quarterly Debt-to-equity history and growth rate from Q4 2016 to Q2 2023.
  • Rapid Therapeutic Science Laboratories, Inc. Debt-to-equity for the quarter ending June 30, 2023 was -173 %, a 23.4% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2023 -173 +52.9 +23.4% Jun 30, 2023
Q1 2023 -175 +119 +40.4% Mar 31, 2023
Q4 2022 -180 +2.25K +92.6% Dec 31, 2022
Q3 2022 -193 -614 -146% Sep 30, 2022
Q2 2022 -226 -710 -147% Jun 30, 2022
Q1 2022 -294 +214 +42.1% Mar 31, 2022
Q4 2021 -2.43K -2.23K -1103% Dec 31, 2021
Q3 2021 421 +571 Sep 30, 2021
Q2 2021 484 +603 Jun 30, 2021
Q1 2021 -507 -397 -362% Mar 31, 2021
Q4 2020 -202 -97.6 -93.6% Dec 31, 2020
Q3 2020 -150 -49.9 -49.8% Sep 30, 2020
Q2 2020 -120 -19.5 -19.5% Jun 30, 2020
Q1 2020 -110 -9.77 -9.76% Mar 31, 2020
Q4 2019 -104 -3.85 -3.84% Dec 31, 2019
Q3 2019 -100 Sep 30, 2019
Q2 2019 -100 Jun 30, 2019
Q1 2019 -100 Mar 31, 2019
Q4 2018 -100 Dec 31, 2018
Q3 2017 -116 Sep 30, 2017
Q2 2017 -133 Jun 30, 2017
Q1 2017 -150 Mar 31, 2017
Q4 2016 -188 Dec 31, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.